抑制间变性淋巴瘤激酶（ALK）活性为CLTC-ALK阳性人弥漫大B细胞淋巴瘤提供治疗途径

资源简介

抑制间变性淋巴瘤激酶（ALK）活性为CLTC-ALK阳性人弥漫大B细胞淋巴瘤提供治疗途径

【数据集背景】

本数据集源站标题为《Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas》。配套论文《Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas》发表于 PLoS ONE（2011），DOI：10.1371/journal.pone.0018436。源站首次发布：2011-04-08。

【数据内容】

源站原始描述：ALK positive diffuse large B-cell lymphomas (DLBCL) are a distinct lymphoma subtype associated with a poor outcome. Most of them feature a t(2;17) encoding a clathrin (CLTC)-ALK fusion protein. The contribution of deregulated ALK-activity in the pathogenesis and maintenance of these DLBCLs is not yet known. We established and characterized the first CLTC-ALK positive DLBCL cell line (LM1). LM1 formed tumors in NOD-SCID mice. The selective ALK inhibitor NVP-TAE684 inhibited growth of LM1 cells in…

【数据结构与技术规格】

文件数 4 个，合计 6.68 MB。Figure_S1.tif：image/tiff，1.96 MB。Figure_S2.tif：image/tiff，2.52 MB。Table_S1.tif：image/tiff，875.11 KB。数据集 DOI：10.1371/journal.pone.0018436。

【主题与分类】

源站学科分类：Cancer、Molecular Biology、Cell Biology。主题标签：inhibition、anaplastic、lymphoma、kinase、provides、therapeutic、cltc-alk-positive、diffuse、lymphomas。

【适用方向】

源站学科分类标注为 Cancer、Molecular Biology、Cell Biology。

【获取与许可】

源站页面：https://plos.figshare.com/articles/dataset/Inhibition_of_Anaplastic_Lymphoma_Kinase_ALK_Activity_Provides_a_Therapeutic_Approach_for_CLTC_ALK_Positive_Human_Diffuse_Large_B_Cell_Lymphomas/137663

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Cerchietti, Leandro; Damm-Welk, Christine; Vater, Inga; Klapper, Wolfram; Harder, Lana; Pott, Christiane; et al. (2016). Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. PLOS ONE. Dataset

【使用注意】

· 源站最后修改于 2023-05-30，引用时请注意版本时效。